Melissa Deck is an experienced biotechnologist specializing in gene therapy and platform development. Currently serving as the Director of Platform at Liberate Bio since March 2023, Melissa previously held a similar role at Carver Biosciences, Inc. from March 2022 to July 2024. Additional leadership experience includes Associate Director positions at Arbor Biotechnologies and Gemini Therapeutics, where responsibilities encompassed gene therapy and scientific oversight. Earlier roles included key positions at Omega Therapeutics and Intellia Therapeutics, where Melissa contributed to innovative therapeutic applications of epigenetics and CRISPR/Cas9 technology. Melissa began a career in research at Novartis Institutes for BioMedical Research and AdvanDx, focusing on gene therapies and antibiotic resistance detection. Melissa obtained a Bachelor of Science in Biology from the University of Massachusetts Lowell in 2008.
This person is not in the org chart
This person is not in any teams
This person is not in any offices